The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

被引：93
作者：
Mitsiades, Constantine S. [1 ]
McMillin, Douglas W. [1 ]
Klippel, Steffen [1 ]
Hideshima, Teru [1 ]
Chauhan, Dharminder [1 ]
Richardson, Paul G. [1 ]
Munshi, Nilchil C. [1 ]
Anderson, Kenneth C. [1 ]
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2007年 / 21卷 / 06期
关键词：
D O I：
10.1016/j.hoc.2007.08.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multiple myeloma (MM) is viewed as a prototypic disease state for the study of how neoplastic cells interact with their local bone marrow (BM) microenvironment. This interaction reflects not only the osteotropic clinical behavior of MM and the clinical impact of the lytic bone lesions caused by its tumor cells but also underlines the broadly accepted notion that nonneoplastic cells of the BM can attenuate the activity of cytotoxic chemotherapy and glucocorticoids. This article summarizes the recent progress in characterization, at the molecular and cellular levels, of how the BM milieu interacts with MM cells and modifies their biologic behavior.
引用
收藏
页码：1007 / +
页数：30
相关论文
共 227 条
  • [21] Bergsagel P L, 1995, Curr Top Microbiol Immunol, V194, P17
  • [22] IN MULTIPLE-MYELOMA, CLONOTYPIC B-LYMPHOCYTES ARE DETECTABLE AMONG CD19(+) PERIPHERAL-BLOOD CELLS EXPRESSING CD38, CD56, AND MONOTYPIC IG LIGHT-CHAIN
    BERGSAGEL, PL
    SMITH, AM
    SZCZEPEK, A
    MANT, MJ
    BELCH, AR
    PILARSKI, LM
    [J]. BLOOD, 1995, 85 (02) : 436 - 447
  • [23] Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
    Bergsagel, PL
    Kuehl, WM
    Zhan, FH
    Sawyer, J
    Barlogie, B
    Shaughnessy, J
    [J]. BLOOD, 2005, 106 (01) : 296 - 303
  • [24] Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment?
    Bissell, MJ
    LaBarge, MA
    [J]. CANCER CELL, 2005, 7 (01) : 17 - 23
  • [25] The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells
    Bolick, SCE
    Landowski, TH
    Boulware, D
    Oshiro, MM
    Ohkanda, J
    Hamilton, AD
    Sebti, SD
    Dalton, WS
    [J]. LEUKEMIA, 2003, 17 (02) : 451 - 457
  • [26] Myeloma bone disease
    Callander, NS
    Roodman, GD
    [J]. SEMINARS IN HEMATOLOGY, 2001, 38 (03) : 276 - 285
  • [27] INSULIN STIMULATION OF AMINOISOBUTYRIC-ACID TRANSPORT IN HUMAN-SKIN FIBROBLASTS IS MEDIATED THROUGH BOTH INSULIN AND TYPE-I INSULIN-LIKE GROWTH-FACTOR RECEPTORS
    CHAIKEN, RL
    MOSES, AC
    USHER, P
    FLIER, JS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (05) : 1181 - 1185
  • [28] Plasma insulin-like growth factor I and prostate cancer risk: A prospective study
    Chan, JM
    Stampfer, MJ
    Giovannucci, E
    Gann, PH
    Ma, J
    Wilkinson, P
    Hennekens, CH
    Pollak, M
    [J]. SCIENCE, 1998, 279 (5350) : 563 - 566
  • [29] STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival
    Chatterjee, Manik
    Jain, Sarika
    Stuehmer, Thorsten
    Andrulis, Mindaugas
    Ungethuem, Ute
    Kuban, Ralf-Juergen
    Lorentz, Heike
    Bommert, Kurt
    Topp, Max
    Kraemer, Doris
    Mueller-Hermelink, Hans Konrad
    Einsele, Hermann
    Greiner, Axel
    Bargou, Ralf C.
    [J]. BLOOD, 2007, 109 (02) : 720 - 728
  • [30] A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    Chauhan, D
    Catley, L
    Li, GL
    Podar, K
    Hideshima, T
    Velankar, M
    Mitsiades, C
    Mitsiades, N
    Yasui, H
    Letai, A
    Ovaa, H
    Berkers, C
    Nicholson, B
    Chao, TH
    Neuteboom, STC
    Richardson, P
    Palladino, MA
    Anderson, KC
    [J]. CANCER CELL, 2005, 8 (05) : 407 - 419
12345678910